Literature DB >> 26936880

Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2.

Daniel W Beury1, Kayla A Carter1, Cassandra Nelson1, Pratima Sinha1, Erica Hanson1, Maeva Nyandjo1, Phillip J Fitzgerald1, Amry Majeed1, Neha Wali1, Suzanne Ostrand-Rosenberg2.   

Abstract

Tumor-induced myeloid-derived suppressor cells (MDSC) contribute to immune suppression in tumor-bearing individuals and are a major obstacle to effective immunotherapy. Reactive oxygen species (ROS) are one of the mechanisms used by MDSC to suppress T cell activation. Although ROS are toxic to most cells, MDSC survive despite their elevated content and release of ROS. NF erythroid 2-related factor 2 (Nrf2) is a transcription factor that regulates a battery of genes that attenuate oxidative stress. Therefore, we hypothesized that MDSC resistance to ROS may be regulated by Nrf2. To test this hypothesis, we used Nrf2(+/+)and Nrf2(-/-)BALB/c and C57BL/6 mice bearing 4T1 mammary carcinoma and MC38 colon carcinoma, respectively. Nrf2 enhanced MDSC suppressive activity by increasing MDSC production of H2O2, and it increased the quantity of tumor-infiltrating MDSC by reducing their oxidative stress and rate of apoptosis. Nrf2 did not affect circulating levels of MDSC in tumor-bearing mice because the decreased apoptotic rate of tumor-infiltrating MDSC was balanced by a decreased rate of differentiation from bone marrow progenitor cells. These results demonstrate that Nrf2 regulates the generation, survival, and suppressive potency of MDSC, and that a feedback homeostatic mechanism maintains a steady-state level of circulating MDSC in tumor-bearing individuals.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26936880      PMCID: PMC4821672          DOI: 10.4049/jimmunol.1501785

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.

Authors:  Donna D Zhang; Shih-Ching Lo; Janet V Cross; Dennis J Templeton; Mark Hannink
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

2.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.

Authors:  Stephanie K Bunt; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

3.  Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2.

Authors:  Changjiang Xu; Mou-Tuan Huang; Guoxiang Shen; Xiaoling Yuan; Wen Lin; Tin Oo Khor; Allan H Conney; Ah-Ng Tony Kong
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs.

Authors:  Analía V Ezernitchi; Ilan Vaknin; Leonor Cohen-Daniel; Ofer Levy; Efrat Manaster; Amal Halabi; Eli Pikarsky; Lior Shapira; Michal Baniyash
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

5.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

Authors:  Bo Huang; Ping-Ying Pan; Qingsheng Li; Alice I Sato; David E Levy; Jonathan Bromberg; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

Authors:  Pratima Sinha; Virginia K Clements; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

7.  Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals.

Authors:  R Yu; W Lei; S Mandlekar; M J Weber; C J Der; J Wu; A N Kong
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

8.  Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Authors:  Daniel W Beury; Katherine H Parker; Maeva Nyandjo; Pratima Sinha; Kayla A Carter; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2014-08-28       Impact factor: 4.962

9.  HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells.

Authors:  Katherine H Parker; Pratima Sinha; Lucas A Horn; Virginia K Clements; Huan Yang; Jianhua Li; Kevin J Tracey; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2014-08-27       Impact factor: 12.701

10.  Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer.

Authors:  Yota Kawasaki; Sumiya Ishigami; Takaaki Arigami; Yoshikazu Uenosono; Shigehiro Yanagita; Yasuto Uchikado; Yoshiaki Kita; Yuka Nishizono; Hiroshi Okumura; Akihiro Nakajo; Yuko Kijima; Kosei Maemura; Shoji Natsugoe
Journal:  BMC Cancer       Date:  2015-01-15       Impact factor: 4.430

View more
  44 in total

1.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 2.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

3.  Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays.

Authors:  Ruth J Davis; Christopher Silvin; Clint T Allen
Journal:  J Immunol Methods       Date:  2016-11-14       Impact factor: 2.303

Review 4.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

5.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Authors:  Ashley Orillion; Ayumi Hashimoto; Nur Damayanti; Li Shen; Remi Adelaiye-Ogala; Sreevani Arisa; Sreenivasulu Chintala; Peter Ordentlich; Chingai Kao; Bennett Elzey; Dmitry Gabrilovich; Roberto Pili
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

6.  Profiling changes in metabolism and the immune microenvironment in lung tumorigenesis.

Authors:  Di Zhang; Ana S Leal; Fawzi Abu Rous; Karen T Liby
Journal:  Ann Transl Med       Date:  2019-07

7.  Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade.

Authors:  Brian P Riesenberg; Ephraim A Ansa-Addo; Jennifer Gutierrez; Cynthia D Timmers; Bei Liu; Zihai Li
Journal:  J Immunol       Date:  2019-07-29       Impact factor: 5.422

Review 8.  Innate sensing of cancer's non-immunologic hallmarks.

Authors:  Ruth Seelige; Stephen Searles; Jack D Bui
Journal:  Curr Opin Immunol       Date:  2017-10-12       Impact factor: 7.486

9.  The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.

Authors:  Chunwan Lu; Priscilla S Redd; Jeffrey R Lee; Natasha Savage; Kebin Liu
Journal:  Oncoimmunology       Date:  2016-10-20       Impact factor: 8.110

Review 10.  The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta; Anu Kauppinen
Journal:  Cell Mol Life Sci       Date:  2018-05-19       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.